Physicians' Academy for Cardiovascular Education

Atrial fibrillation

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Where are we with HF patients with AF?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
##SCROLLER_ITEMS_FULL_TITLE##

Translating new clinical trial data of DOACs for stroke prevention into clinical practice

3' education - Mar. 30, 2014 - VBWG at ACC - Michael Ezekowitz MD, PhD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt
Prof. Verheugt talks about the results of the AFIRE trial, in which monotherapy with rivaroxaban was compared with a combination therapy of rivaroxaban and antiplatelet agents in CAD patients with AF.

ESC 2019 Prof. Verheugt talks about the results of the AFIRE trial, in which monotherapy with rivaroxaban was compared with a combination therapy of rivaroxaban and antiplatelet agents in CAD patients with AF.

Artificial intelligence helps pick up AF in ECG acquired during normal sinus rhythm

Literature - Aug. 14, 2019 - Attia Z et al., - The Lancet 2019

An AI model permits point-of-care identification of individuals with a high likelihood of AF, in normal sinus rhythm ECGs, based on subtle findings due to structural changes in the atria.

Factor Xa inhibitor effective and safe in AF patients with liver disease

Literature - July 23, 2019 - Qamar A, et al. - J Am Coll Cardiol 2019
In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.

In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.

No reduction in mortality and CV outcomes with catheter ablation in AF

Literature - Apr. 2, 2019 - Packer DL, et al. - JAMA 2019

In the CABANA trial, catheter ablation did not result in a reduction of death, disabling stroke, serious bleeding or cardiac arrest in symptomatic AF patients compared to drug therapy.

Delayed cardioversion non-inferior to early cardioversion in recent-onset AF

Literature - Apr. 2, 2019 - Pluymaekers NAHA et al. - New Eng J Med 2019
A wait-and-see strategy with rate-control drugs was non-inferior to early pharmacologic or electric conversion in achieving sinus rhythm among patients with recent-onset symptomatic AF.

A wait-and-see strategy with rate-control drugs was non-inferior to early pharmacologic or electric conversion in achieving sinus rhythm among patients with recent-onset symptomatic AF.

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD
Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

Antithrombotic regime with NOAC but no aspirin most favorable for patients with AF and ACS/PCI

News - Mar. 17, 2019

ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD
Dr. Valentine chaired the press conference on the Apple Heart Study. He summarizes the results and the response to the AF-screening results obtained with Apple Watch.

ACC 2019 Dr. Valentine chaired the press conference on the Apple Heart Study. He summarizes the results and the response to the AF-screening results obtained with Apple Watch.

Smart watch can detect AF: a beginning of an era with new wearable technology to screen AF?

News - Mar. 15, 2019
The Apple Heart Study in over 400.000 people, showed that Apple Watch could detect AF in 0.5% of participants, after having been alerted by the app as having an irregular heartbeat.

ACC 2019 The Apple Heart Study in over 400.000 people, showed that Apple Watch could detect AF in 0.5% of participants, after having been alerted by the app as having an irregular heartbeat.

DOACs may reduce thromboembolic events in patients with mitral stenosis and AF

Literature - Mar. 13, 2019 - Kim JY et al. - JACC 2019

In an exploratory analysis of insurance data, DOAC use reduced stroke or systemic embolism in patients with mitral stenosis and AF compared to warfarin.

Better clinical outcomes with DOACs vs. warfarin in patients with NVAF and low body weight

Literature - Mar. 5, 2019 - Lee S-R et al. - JACC 2019
An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.

An Asian cohort of adults with non-valvular AF and low or very low body weight (<60/50 kg), showed better effectiveness and safety with regular and reduced DOAC dose, compared with warfarin.

Fat and fat-free mass causally and independently linked to incident AF

Literature - Feb. 26, 2019 - Tikkanen E et al., - Eur Heart J. 2019

Both observational and mendelian randomization analyses suggest that fat-free mass and fat mass are both causally associated with incident AF. The link between fat mass and AF was stronger in women.